http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CH-560049-A5
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66ba6770db496b5879df0f1f62ee52b6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-26 |
| filingDate | 1971-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1975-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CH-560049-A5 |
| titleOfInvention | Thymus extracts with antileucopenic activities - by extraction and hydrolysis of thymus glands, then deproteinising |
| abstract | A thymus extract is prepd. by repeatedly treating finely cut thymus glands from young mammals, with a hydrolysing soln. at various temps., centrifuging the liq. obtd. and standing the supernatant at various temps., pH-values and times, filtering after every temp. change. The resultant liq. is partly frozen, the ice removed and the extract obtd. is diluted and filtered. (I) have antileucopenic and antibody-forming activity. They may be used in the treatment of primary and sec. leucopenia after treatment with bone marrow poisons or myelo-toxic influences such as irradiation, X-ray treatment, cobalt irradiation, Betatron, carcinostatic therapy etc. The activity of (I) is considerably higher than that of known antileucopenic agents. No local-or general side-effects are shown. |
| priorityDate | 1971-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.